Clinical Trial Detail

NCT ID NCT02909452
Title Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Syndax Pharmaceuticals
Indications

Advanced Solid Tumor

Therapies

Entinostat + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.